Voyager Therapeutics (NASDAQ:VYGR) had its price objective upped by Nomura from $26.00 to $37.00 in a report issued on Thursday, June 20th, The Fly reports. Nomura currently has a buy rating on the stock.
VYGR has been the topic of several other research reports. HC Wainwright raised their target price on shares of Cytokinetics from $21.00 to $26.00 and gave the stock a buy rating in a report on Monday, May 6th. Cantor Fitzgerald set a $8.00 target price on shares of Aerpio Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, March 5th. Cowen restated a hold rating and issued a $109.00 target price on shares of United Therapeutics in a report on Wednesday, February 27th. Wedbush restated an outperform rating and issued a $74.00 target price on shares of Tempur Sealy International in a report on Tuesday, June 18th. Finally, Zacks Investment Research upgraded shares of Zynex from a hold rating to a buy rating and set a $5.50 target price on the stock in a report on Saturday, March 2nd. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Voyager Therapeutics presently has an average rating of Buy and a consensus price target of $27.44.
Shares of VYGR traded down $0.17 during mid-day trading on Thursday, reaching $25.50. 433,299 shares of the company’s stock traded hands, compared to its average volume of 512,757. The firm’s 50-day simple moving average is $25.27. The company has a market cap of $945.49 million, a PE ratio of -9.27 and a beta of 2.57. Voyager Therapeutics has a 12 month low of $7.76 and a 12 month high of $28.79.
A number of large investors have recently added to or reduced their stakes in the stock. SG3 Management LLC purchased a new position in Voyager Therapeutics in the 1st quarter worth about $57,000. Metropolitan Life Insurance Co. NY grew its stake in shares of Voyager Therapeutics by 449.4% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after purchasing an additional 7,401 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of Voyager Therapeutics by 74,766.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,492 shares of the company’s stock valued at $86,000 after purchasing an additional 4,486 shares during the period. Bank of America Corp DE grew its stake in shares of Voyager Therapeutics by 211.0% during the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after purchasing an additional 7,217 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Voyager Therapeutics by 66.8% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after purchasing an additional 4,559 shares during the period. Institutional investors and hedge funds own 73.78% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Further Reading: What Are Cryptocurrencies?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.